Major surgery within 4 weeks prior to randomization.
Major surgery within 28 days of starting study treatment and patients must have recovered from any effects of any major surgery
Patients must not have received any major surgery or immunotherapy within 28 days prior to registration
No major surgery =< 4 weeks before pre-registration
Major surgery within 2 weeks prior to randomization: patients must have recovered from any effects of any major surgery
No major surgery =< 14 days prior to registration
No major surgery within 28 days prior to randomization
No major surgery within 28 days prior to registration
Patient must have not had any major surgery or radiation within 28 days prior to step 1 registration; diagnostic thoracotomies and laparoscopies are not considered major surgeries
Major surgery must not have occurred within 2 weeks prior to enrollment and patients must have recovered from any effects of any major surgery
Major surgery within 30 days prior to enrollment.
Patient has had major surgery within 14 days prior to treatment start or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery
Major surgery within 4 weeks
Subject has had major surgery within 6 weeks prior to Cycle 1 Day-2 (subjects must have completely recovered from any previous surgery prior Cycle 1 Day-2).
Major surgery =<4 weeks before first dose of study drug or incomplete recovery from a prior major surgical procedure
Patients who have undergone major surgery within 4 weeks prior to registration are not eligible
Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start
Major surgery other than diagnostic surgery, within 4 weeks prior to the first dose of test drug, minor surgery including diagnostic surgery within 2 weeks (14 days) excluding central IV port placements and needle aspirate/core biopsies. Radio frequency ablation or transcatheter arterial chemoembolization within 6 weeks prior to the first dose of test drug.
Major bowel surgery which in the opinion of the Investigator should exclude the patient
History of major surgery within 30 days prior to trial initiation
8. Major surgery within 4 weeks prior to first dose of TAB001 or still recovering from prior surgery;
Have a planned major surgery.
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Major surgery within 3 weeks of scheduled C1D1 dosing.
Major surgery within 28 days of first dose AMG 757
Major surgery or radiation therapy within 4 weeks prior to the first study dose
Major surgery ?28 days or major radiation therapy ?14 days prior to enrollment.
Patients must have completed any major surgery or open biopsy >= 4 weeks from start of treatment
Recovered from any previous surgery and no history of major surgery within the last 28 days prior to start of study drug
No major surgery within 30 days of first study treatment.
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery within 2 weeks of the first dose of study treatment (mediastinoscopy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery)
Recent major surgery within 4 weeks prior to first infusion
Major surgery within 4 weeks of study treatment start
Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days prior to screening; no major surgery, other than diagnostic surgery, is allowed within 4 weeks prior to treatment in the study
Patients who are less than 4 weeks post-op after major surgery
Major surgery =< 14 days prior to registration or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 28 days of study day 1 with the exception of biopsy and insertion of central venous catheter.
Subject had major surgery within 4 weeks prior to randomization (kyphoplasty is not considered major surgery); subjects should have been fully recovered from any surgical related toxicities.
Major surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1, without complete recovery.
Major surgery within 2 weeks prior to trial entry;
Major surgery within 3 weeks prior to the start of study treatment
Major surgery within 28 days before Cycle 1 Day 1
Major surgery within 4 weeks of enrollment
Major surgery within 28 days of the first dose of study drug
Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.
Have had major surgery or bone fracture within 28 days before first dose of study treatment
?4 weeks since any major surgery and fully recovered.
Has had major surgery in the past 4 weeks.
Major surgery within 4 weeks of first dose of study drug
Major surgery, anti-cancer therapy, or radiation therapy within 4 weeks of study treatment
Major surgery within 3 weeks prior to first dose
Participants who have had major surgery within 2 weeks prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Participant has not fully recovered from major surgery or significant traumatic injury prior the first dose of study drug or expects to have major surgery during the study period or within 6 months after the last dose of study drug
Major surgery within 3 weeks prior to first dose of study treatment, and patients must have recovered from the effects of surgery
Major surgery
Major surgery within 14 days before enrollment
Major surgery within 4 weeks before the first dose of study drug
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Patients who have had major surgery within 4 weeks prior to registration are not eligible
Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.
Major surgery within 6 weeks of enrollment
Major surgery within 28 days prior to initiation of study drug.
Major surgery less than 28 days prior to study entry.
History or major surgery within 4 weeks before the first dose of study treatment, or not recovered from prior surgery
Major surgery within 14 days prior cycle 1, day 1
Major surgery within 2 months before planned first dose of study drug
A minimum of 4 weeks from any major surgery prior to registration
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy prior to registration
Major surgery within 28 days prior to initiating therapy
Major surgery within 3 weeks prior to first dose, prior peripheral stem cell transplant within 12 weeks of study enrollment
Major surgery in the last three weeks
Major surgery within 21 days prior to first dose
At least 2 weeks must have elapsed since undergoing major surgery
Patients who may require major surgery during the course of the study
At least 3 weeks from major surgery
Major surgery within 12 weeks before the first dose of study treatment. Complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment. Minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgery are not eligible
Major surgery or radiation within 4 weeks prior to study entry
Participants who have undergone major surgery within 14 days of starting the study treatment, or participants who have not recovered to baseline status from the effects of major surgery received more than 14 days prior.
Has had major surgery within 21 days before cycle 1, day 1
Participant had major surgery within 28 days prior to Study Day 1.
Major surgery: 6 weeks
Major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery
Prior major surgery within 12 weeks or prior major surgery from which the patient has not sufficiently recovered yet
PHASE II EXCLUSION CRITERIA: Prior major surgery within 12 weeks or prior major surgery from which the patient has not sufficiently recovered yet
Major surgery within 4 weeks before the start of study therapy.
Major surgery within 14 days before enrollment
Major surgery within 4 weeks before enrollment
Major surgery, radiation therapy or systemic anti-cancer therapy within 2 weeks of starting study treatment
Major surgery within 28 days prior to first dose of protocol therapy
Major surgery within 2 weeks of starting the study treatment, or not recovered to baseline status from the effects of surgery received > 2 weeks prior
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Reasonably recovered from preceding major surgery as judged by the investigator or no major surgery within 4 weeks prior to the start of Day 1 treatment
All major surgery including prior surgery to the brain within 3 weeks of commencement of study therapy
Major surgery, radiation, or treatment with any other investigational drug within 2 weeks of study treatment
Participants must be >= 28 days from any major surgery
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Prior major treatment-related surgery completed at least 4 weeks prior to study drug administration;
Participants who have undergone major surgery within 14 days of starting the study treatment, or participants who have not recovered to baseline status from the effects of major surgery received more than 14 days prior
Major surgery within 4 weeks prior to the first study dose.
Major surgery within 4 weeks prior to randomization.
Patients who underwent major surgery within 4 weeks before the planned day for the first treatment
Major surgery without full recovery or within 3 weeks before planned randomization;
Not recovered from AEs and/or complications from major surgery prior to first dose
At least 4 weeks since major surgery or radiation therapy
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
No history of major surgery =< 28 days of registration
Major surgery within 4 weeks prior to randomization.
Major surgery within 2 weeks of the first dose of study drug
Major surgery within 2 months prior to enrollment or minor surgery within 7 days of the first day of treatment
Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
Has had major surgery within 4 weeks before first study drug administration
Major surgery within 4 weeks of first dose of study drug
Major surgery within 4 weeks before the start of study therapy.
Major surgery within 14 days before enrollment
Have had major surgery other than a minor outpatient procedure within 4 weeks prior to dose assignment or have not recovered from major side effects of the surgery if more than 4 weeks have elapsed since surgery
Patients who have had major surgery or significant traumatic injury within 4 weeks prior to registration, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study
Major surgery within 4 weeks of first dose of study drug
Major surgery, other than diagnostic surgery, within 2 weeks prior to Cycle 1 Day 1, without complete recovery.
Prior chemotherapy and/or immunotherapy within 14 days before enrollment; major surgery within 14 days before enrollment and minor surgery within 7 days prior to cycle 1 day 1
Any major surgery within 4 weeks prior to the first dose of study drug.
Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting INC280 or who have not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedure
Major surgery within 4 weeks of the first dose of study treatment
Major surgery within 14 days before enrollment
Recovery from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment; endoscopic debridement of RRP lesions is NOT considered a major surgery
Any major surgery, as determined by the Investigator, within 4 weeks of IMP administration
Patients who have undergone major surgery =< 4 weeks prior to starting study treatment or who have not recovered from side effects of such procedure
Major surgery =< 14 days before study registration
Major surgery within 28 days prior to the first study treatment
Major surgery within 4 weeks or minor surgery within 2 weeks before registration or scheduled for surgery during the projected course of the study; wounds will be completely healed prior to study entry and patients recovered from all toxicities from surgery; placement of vascular access device is not considered major or minor surgery in this regard
Subject has had major surgery within 28 days prior to study day 1
Major surgery within 28 days of study day 1 with the exception of biopsy and long line insertion
Major surgery within 14 days before enrollment
Patients who have undergone major surgery < 4 weeks or minor surgery < 2 weeks prior to registration; wounds must be completely healed prior to study entry and patients recovered from all toxicities from surgery; placement of a vascular access device is not considered major or minor surgery in this regard
Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
Have had recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular access
Major surgery: ?2 weeks
Major surgery ? 2 weeks prior to starting CC-90002.
Patients who have had major surgery within 6 weeks prior to the first dose of study drug or have major surgery planned during the first 12 weeks after MT-3724 has finished.
Radiation therapy or major surgery within 4 weeks prior to first dose of study agent
Major surgery other than diagnostic surgery =< 4 weeks prior to registration
Major surgery within 14 days before randomization.
Patients with major surgery within 28 days prior to trial enrollment
Patients may not have had major surgery within 10 days of enrollment, or minor surgery within 7 days of enrollment; examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint; the decision about whether a surgery is major or minor can be made at the discretion of the treating physician
Reasonably recovered from preceding major surgery as judged by the investigator or no major surgery within 4 weeks prior to the start of Day 1 treatment
Patients who have had major surgery must be fully recovered and >= 4 weeks post-operative prior to enrolling on study
Patients who have undergone major surgery within the 2 weeks prior to starting study treatment or who have not fully recovered from previous surgery
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patient has undergone major surgery, other than diagnostic surgery (ie, surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Day 1 of treatment in this study.
Patients who have had major surgery within 3 weeks prior to enrollment are not eligible; procedures such as placement of a central vascular catheter, or limited tumor biopsy, are not considered major surgery
Major surgery =< 14 days prior to study registration
Incomplete recovery from major surgery within 4 weeks of enrollment
Major surgery within 28 days prior to treatment or major surgery planned during the next 6 months
Major surgery within 1 month prior to enrollment
At least 4 weeks from completion of major surgery and a healed surgical incision
Has had major surgery within 21 days before cycle 1, day 1.
Major surgery within 4 weeks prior to cycle 1, other than for diagnosis.
Subjects must not have received chemotherapy, or undergone major surgery within 2 weeks and radiotherapy within 24 hours prior to enrollment
Major surgery must have been completed ? 4 weeks prior to starting treatment day 1; patient must be sufficiently recovered and stable from surgery prior to treatment day 1
Patients that have had major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Has not had major surgery within 28 days prior to starting study treatment. Central venous access surgeries and/or placements would not be considered as major surgery.
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
No major surgery within 4 weeks of first dose of sEPHB4
Major surgery ? 14 days prior to study registration
Major surgery or radiation therapy within 14 days before study drug administration
Major surgery =< 4 weeks prior to registration
Recent major surgery (within 6 weeks prior to the start of cycle 1, day 1) other than for diagnosis
Major surgery (requiring general anesthesia) within 30 days prior to initiation of therapy
Major surgery within 2 weeks of starting study treatment and subjects must have recovered from any effects of any major surgery.
CRITERIA SPECIFIC FOR COHORT #2 (MCL): Major surgery within 4 weeks of first dose of study drug
Major surgery within 4 weeks of first dose of study drug
Major surgery within 2 weeks prior to first dose of study drug
Major surgery within 4 weeks before the start of study therapy.
Major surgery within 28 days of registration
Major surgery within 6 weeks prior to study day 1 (subjects must have completely recovered from any previous surgery prior to study day 1)
History of major surgery within 4 weeks prior to first dose on this study
Major surgery (as defined by the Investigator): ?4 weeks
Major surgery within 4 weeks before the start of study therapy.
Major surgery within 28 days prior to starting study drug or has not recovered from major side effects of the surgery.
Major surgery within 4 weeks of enrollment, or a wound that has not fully healed
Recent major surgery (within 6 weeks prior to the start of study treatment) other than for diagnosis
Major surgery within 4 weeks of first dose of study medications. Minor procedures (e.g. port placement, endoscopy with intervention) within 2 weeks of first dose of study medications are allowed
No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment
Known bleeding risk including serious hemorrhage or hemoptysis within the last 3 months; major surgery within the past 8 weeks or minor surgery within the past 4 weeks
Major surgery within 28 days of enrollment.
Major surgery within 14 days before the first dose of any study drug or a scheduled surgery during the study period
Major surgery within 4 weeks of initiation of study drug
Any major surgery, chemotherapy or immunotherapy within the last 21 days
The participant has electively planned or will require major surgery during the course of the study.
Major surgery within 28 days prior to first dose of study drug
Major surgery or radiotherapy within 21 days prior to Day 1 of Cycle 1 or anticipation of needing such procedure while receiving study treatment
Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry
Major surgery (requiring general anesthesia) within 3 months prior to dosing.
Major surgery within 28 days prior to randomization.
At least 3 weeks between major surgery and planned start of study treatment; major incisions must have healed
Major surgery within 21 days of starting protocol treatment
Major surgery within 6 weeks of first dose of study medications; minor procedures (e.g. port placement, endoscopy with intervention) within 4 weeks of first dose of study medications
Major injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period
Patients who had undergone any major surgery within 4 weeks of study enrollment
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Major surgery within 4 weeks prior to enrollment (day 1)
Major surgery within 4 weeks before screening
Major surgery and surgery for brain metastases within 28 days prior to screening start; of note, intravenous port placement is not considered as a major surgery
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from the side-effects of surgery
Major surgery or a wound that has not fully healed within 4 weeks of enrollment
Major surgery within 14 days before the first dose of any study drug or a scheduled surgery during study period
Major surgery =< 4 weeks prior to registration
Major surgery within 12 weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment; all clinically relevant ongoing complications from prior surgery should be resolved before the first dose of study treatment
Major surgery within 4 weeks prior to enrollment
Major surgery within the past 2 months
No major surgery within 14 days of start of study treatment
Major surgery within 2 weeks prior to registration or first dose of drug
A minimum of 4 weeks from any major surgery prior to cycle 1 day 1
Major surgery =< 4 weeks prior to registration (the surgical incision should be fully healed prior to drug administration or radiation therapy)
Patients who have had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 2 weeks prior to starting study drug or who have not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedure
Major surgery within 28 days of starting study treatment
Major surgery within 14 days before enrollment
Have electively planned or will require major surgery during the course of the study.
Patients, who have had a major surgery or significant traumatic injury (injury requiring > 4 weeks [28 days] to heal) within 4 weeks (28 days) of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that are expected to require major surgery, other than cytoreductive nephrectomy +/- retroperitoneal lymph node dissection, during the course of the study.
Subject has had major (per Investigator discretion) surgery, with the exception of tumor resection, within 21 days from first dose of study drug.
Major surgery =< 14 days prior to starting study treatment or who have not recovered from side effects to < grade 2 CTCAE
Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
Major surgery within 4 weeks of enrollment
Major surgery, radiotherapy or infection requiring therapy within 14 days of starting treatment
History of recent major surgery within 6 weeks prior to the start of cycle 1, day 1 other than for diagnosis
Major surgery within 12 weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior surgery are not eligible
< 2 weeks since major surgery (i.e., laparotomy or thoracotomy)
Major surgery =<14 days prior to registration
Prior surgery: patients may not have had major surgery within 28 days of enrollment, or minor surgery within 7 days of enrollment; examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint; the decision about whether a surgery is major or minor can be made at the discretion of the treating physician
Major surgery within 2 weeks prior to first dose of study drug
Major surgery performed within 4 weeks of study entry
Major surgery within 28 days prior to day 1 of study treatment from which the patient has not completely recovered
Major surgery within 4 weeks of first dose of investigational product
Recent major surgery within 4 weeks prior to starting study treatment. Minor surgery within 2 weeks of starting study treatment. Patients must be recovered from effects of surgery
Recent major surgery within 4 weeks prior to entry into the study (excluding the placement of vascular access and defunctioning stoma or any other surgical procedures not considered major by the investigator) that would prevent administration of study treatment
Has had major surgery within 4 weeks or minor surgery within 2 weeks prior to study day 1; subjects must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Major surgery within 2 weeks before day 1.
Major surgery within 2 weeks of first dose of study drug
Undergone major surgery within 14 days of the initial dose of study drug
Major surgery (eg, nephrectomy) less than 28 days prior to the first dose of study drug
Major surgery other than diagnostic surgery within 28 days of Study Day 1
Major surgery (within 4 weeks prior to the start of cycle 1), other than for diagnosis
Major surgery within 4 weeks of initiation of study drug
Major surgery less than 6 weeks prior to the first dose of study drug; minor surgery less than 4 weeks prior to the first dose of study drug
Subject has had major surgery within 14 days prior to registration or has not recovered from major side effects of the surgery (tumor biopsy is not considered as major surgery).
Patient has had major surgery (e.g., intra足thoracic, intra足abdominal or intra足pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video足-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these procedures
Scheduled for major surgery after baseline;
Any major surgery within 21 days prior to enrollment
Recent major surgery within 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular access
Major surgery (eg, nephrectomy) less than 28 days prior to the first dose of study drug
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Prior major surgery or gastrointestinal perforation within 28 days of enrollment
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Major surgery within 4 weeks of first dose of study drug
Prior major surgery within 2 weeks prior to the first dose of study drug or who has not recovered adequately from the toxicity and/or complications from the intervention
Major surgery other than diagnostic surgery =< 4 weeks prior to registration
Subject who has not recovered from the effects of any major surgery prior to initial treatment
No major surgery within 4 weeks prior to enrollment
Recent major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
Major surgery, other than diagnostic surgery, occurring 4 weeks prior to study entry; splenectomy will not be considered an exclusionary major surgery
Surgery: at least 2 weeks since undergoing any major surgery and must be recovered from effects of surgery
Major surgery: only patients who are not anticipated to need major surgery within the next 3 months of enrollment are eligible
Major surgery within 14 days of registration and patients must have recovered from any effects of any major surgery
Had major surgery ? 4 weeks of C1D1
Patients with major surgery within 30 days prior to entering the study
Major surgery =< 4 weeks prior to registration
Patients, who have had a major surgery or significant traumatic injury (injury requiring > 4 weeks [28 days] to heal) within 4 weeks (28 days) of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that are expected to require major surgery during the course of the study
Major surgery =< 14 days prior to registration
Major surgery =< 28 days prior to registration; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy
Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment
Major surgery (requiring general anesthesia) within 2 weeks prior to initiation of therapy
Major surgery within 14 days before the first dose of any study drug or a scheduled surgery during study period
Major surgery within 14 days prior to starting study drug or has not recovered from surgical complications (tumor biopsy is not considered as major surgery)
Major surgery* within 28 days before enrollment.
Major surgery within 4 weeks of first dose of study drug
Recent major surgery (within 6 weeks prior to the start of study treatment) other than for diagnosis
Any major surgery within 4 weeks or a diagnostic procedure (eg incision, needle biopsy) within 1 day of study drug administration
Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
Major surgery within 4 weeks prior to day 1 of the study or who have not recovered from prior surgery
Major surgery within 3 weeks prior to first dose
A minimum of 4 weeks from any major surgery prior to registration
Major surgery within 1 month prior to enrollment
Had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgery
Major surgery (major according to the Investigator's assessment) performed within 12 weeks prior to first trial treatment or planned within 12 months after screening, e.g.,hip replacement
Patients who have had major surgery must be fully recovered and require a recovery period of >= 4 weeks prior to enrolling on study
Has had any major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered major surgery) resulting from a prior surgery
Major surgery within 4 weeks of first dose of study drug
Major surgery within 14 days before enrollment
Major surgery within 4 weeks before first dose of study drug
Received major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK2879552 administration
Major surgery or a wound that has not fully healed within 4 weeks of enrollment
Major surgery =< 14 days prior to registration
Major injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period
Major surgery within 4 weeks of first dose of study drug
Major surgery within 14 days before enrollment
Major surgery within 12 weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior surgery are not eligible
Major surgery, other than diagnostic surgery, within 4 weeks prior to day 1, without complete recovery from the surgical procedure
Major surgery or a wound that has not fully healed within 4 weeks of enrollment
Major surgery within prior 4 weeks and minor surgery within 7 days;
At least 21 days have passed since major surgery
Have had recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular access
Patients who have had major surgery within 4 weeks prior to registration are not eligible
Major surgery within 30 days prior to the start of study medication.
At least 30 days from major surgery before study enrollment, with full recovery
Reasonably recovered from preceding major surgery as judged by the Investigator or no major surgery within 4 weeks prior to the start of Day 1 treatment
Major surgery (as defined by the investigator) within 4 weeks or thoracotomy for pulmonary metastases within 2 weeks prior to first dose of treatment or if still recovering from prior surgery; local surgery of isolated lesions for palliative intent is acceptable
Subjects who have had major surgery (such as nephrectomy) or chemotherapy within 2 weeks prior to first dose of drug
Major surgery within 6 weeks prior to study day 1 (subjects must have completely recovered from any previous surgery prior to study day 1); biopsy, diagnostic tonsillectomy, airway tumor debulking or excisional lymph node biopsy do not constitute major surgery
Major surgery in the last two weeks of starting study therapy; this does not include procedures like biopsy (needle or excisional) or port placement as these are not considered as major surgery
Any major surgery (within 4 weeks of Study Day 1, or has not recovered from the effects of such surgery).
Major surgery within 30 days prior to start of treatment
Major surgery within the four weeks prior to initiating protocol therapy
Major surgery within 4 weeks of first dose of study drug
Major surgery within 4 weeks of drug administration
Major surgery without full recovery or major surgery within 3 weeks of screening
Major surgery =< 4 weeks prior to registration
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery =< 14 days before study registration
Patients who have had major surgery within 21 days before cycle 1, day 1
Major surgery other than diagnostic surgery within 28 days of Study Day 1
Patient who has undergone major surgery =< 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedure
Major surgery =< 28 days prior to registration
Major surgery within 3 weeks prior to event 1
Major surgery =< 4 weeks prior to registration
Major surgery within 4 weeks of study entry, or wound that is not healed from prior surgery or\r\ntrauma
Major surgery within 14 days before enrollment
Patients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (all surgical wounds must be fully healed); for the purpose of this criterion, a major surgical procedure is defined as one requiring the administration of general anesthesia (tumor biopsy is not considered as major surgery)
The patient is not recovered from minor or major surgery and is less than 4 weeks from major surgery prior to starting treatment with pembrolizumab
CAPMATINIB EXCLUSION CRITERIA: Major surgery (e.g., intrathoracic, intraabdominal or intrapelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting capmatinib; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study >= 1 week after the procedure
Major surgery within 14 days before enrollment
At least 4 weeks from major surgery
Major surgery within 12 weeks of enrolment
Major surgery within 4 weeks of starting study treatment
Any major surgery, chemotherapy or immunotherapy within the last 14 days
Major surgery within 28 days prior to C1D1.
Has had major surgery within 21 days before cycle 1, day 1
Patient has had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these procedures
Patients who have had major surgery within 4 weeks prior to study registration or those who have not recovered from complications from a surgery more than 4 weeks prior to registration
Major surgery (including primary tumour surgery, excluding placement of vascular access) within 4 weeks of the first dose of study drug
Major surgery within 28 days prior to study registration or those patients who have not recovered adequately from prior surgery
Has had major surgery within 3 weeks prior to enrollment
Major surgery within 30 days prior or during the study period
Major surgery within 14 days prior to start of study treatment
Subject has had major surgery within 21 days prior to the first dose of ABBV-399.
Must not have had major surgery or radiation therapy within 14 days of starting study treatment
Have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery within 4 weeks of registration is prohibited
Subjects must not have received chemotherapy, or undergone major surgery within 2 weeks and radiotherapy within 24 hours prior to enrollment
Major surgery or treatment with any other investigational agent within 4 weeks
Subject has had major surgery within 28 days prior to study day 1
Major surgery within 21 days prior to randomisation
Major surgery within 4 weeks of initiation of therapy; clearance letter from primary physician required
Major surgery within 14 days before the first dose of study drug
Major surgery within 14 days before enrollment; the PI will serve as the final arbiter as to what constitutes major surgery
Major surgery within 4 weeks prior to first study dose
Major surgery requiring a prolonged hospitalization or recovery within 21 days before day 1 of study drug
Major surgery within 14 days before enrollment
Major surgery within 14 days before enrollment
Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
Major surgery in the past 4 weeks.
Major surgery within 14 days before enrollment
Major surgery within 14 days before the first dose of study drug and have not recovered fully from any complications from surgery.
Had major surgery within 4 weeks prior to study drug treatment.
Major surgery (within 4 weeks prior to the start of cycle 1), except for procedures that are performed for diagnostic purposes
Major injuries and/or surgery with then past 4 weeks prior to the start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period
Subjects who have received radiation therapy, major surgery, other locoregional therapy, within 4 weeks prior to the first dose of study drug
Patient has had major surgery (e.g. intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these procedures
A history of any major surgery within 6 weeks prior to dosing
Major surgery (e.g. thoracic, abdominal, vascular, neurosurgery) within 28 days prior to registration on the study
Major surgery =< 14 days prior to registration or have not recovered from side effects of such therapy
Any major surgery within the last 3 weeks
Major surgery within four weeks before day 1
Major surgery or a wound that has not fully healed within 4 weeks of initiation of therapy
Major surgery within 30 days prior to date of randomization.
Surgery within 3 weeks prior to enrollment
Patients who have had major surgery within 4 weeks of initiation of study medication
Major surgery in the past 16 weeks
Major surgery or radiation therapy within 4 weeks prior to the Baseline Visit.
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery within two weeks prior to trial entry
Major surgery within 4 weeks prior to registration
> 4 weeks since major surgery
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Major surgery within 21 days prior to enrollment
Patients had a major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedure
>= 2 weeks since major surgery
Major surgery, other than diagnostic surgery, within 2 weeks
Major surgery within 3 weeks of the start of study treatment, without complete recovery
Patients may have received prior surgery provided that at least 28 days have elapsed since major surgery (thoracic or other major surgeries) and the patient has recovered from all associated toxicities. Patients must have disease outside of the previous surgical resection area or a new lesion must be present.
Must have had no major surgery within 28 days prior to enrollment.
Major surgery, or not recovered from major surgery within 4 weeks before the first dose of study treatment
Patients who have undergone major surgery < 4 weeks of initiation of study medication or who have not recovered from side effects of such procedure
Major surgery within 2 weeks of the start of study treatment, or ongoing complications from surgeries performed previously
Major surgery within 21 days prior to first dose
Any of the following prior therapies:\r\n* Radiation to >= 25% of bone marrow\r\n* Major surgery (i.e., laparotomy), open biopsy, or significant traumatic injury =< 4 weeks prior to registration; minor surgery =< 2 weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery in this regard
Patients with major surgery or radiation therapy within 4 weeks prior to first study dose.
Major surgery within 4 weeks prior to day 1
Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without complete recovery
Patients who have had major surgery within 6 weeks of enrollment in the study
Patients with major surgery within 30 days prior to entering the study
A minimum of 4 weeks from any major surgery prior to start of study drug
Planned major surgery
Major surgery within 4 weeks prior to Randomization Visit
Major surgery =< 14 days before study registration
The patient has undergone major surgery within 28 days prior to first dose of protocol therapy, or minor surgery/subcutaneous venous access device placement within 2 days prior to first dose of protocol therapy; the patient has elective or planned major surgery to be performed during the course of the clinical trial
Major surgery as defined by the investigator within 2 weeks of the first dose of study treatment (minimally invasive procedures such as bronchoscopy, tumor biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery)
Major surgery, other than diagnostic surgery, within 4 weeks prior to first dose, without complete recovery.
Major surgery within 4 weeks of first dose of study drug
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients must not have any major surgery or radiation therapy within 14 days of start of study treatment
Major surgery within 30 days before the initiation of study treatment
Major surgery (requiring general anesthesia) within 3 months prior to dosing.
Have major surgery, other than diagnostic surgery, within 4-weeks prior to Day 1
Prior systemic chemotherapy, major surgery, or thoracic radiation within 3 weeks of study initiation.
Major surgery <=4 weeks before the first dose of study treatment. Subjects must have also fully recovered from any surgery (major or minor) and/or its complications before initiating study treatment.
Failure to recover from major surgery or traumatic injury within 4 weeks or minor surgery within 2 weeks prior to Day 1 of treatment.
Major surgery =< 14 days prior to study registration
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Major surgery within 4 weeks prior to study treatment.
Subject has had major surgery within the last 28 days
Major surgery within 14 days before the first dose of any study drug or a scheduled surgery during study period
Major surgery within 14 days before enrollment.
Major surgery in last 4 weeks, minor surgery in the last 2 weeks
Major surgery within 30 days prior to enrollment.
Major surgery within 4 weeks prior to starting INC280
Major surgery (eg., requiring general anesthesia) within 3 weeks before screening, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study
Patients who have undergone major surgery <4 weeks prior to starting study drug.
Have had major surgery ? 2 weeks prior to starting treatment with Andes-1537 or who have not recovered from side effects of such surgery
Major surgery/surgical therapy for any cause within 4 weeks of Screening;
Major surgery within four weeks before cycle 1 day 1
Patients who have undergone major surgery within 21 days prior to registration are NOT eligible for participation
Patient had major surgery within 4 weeks prior to the first dose.
At least 4 weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities.
Major surgery within 4 weeks prior to first dose of STA-9090
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery within 4 weeks or minor surgery within 2 weeks of the start of study drug.
Major surgery, other than diagnostic surgery, within 4 weeks prior to the first dose of test drug.
Patients who have had major surgery within the past 14 days.
Major surgery within 4 weeks prior to study entry
Major surgery or invasive intervention within 4 weeks prior to first dose
Any major surgery within the last four weeks.
214 Major surgery within 28 days of first dose AMG 562.
Major surgery within 4 weeks prior to study enrollment.
Has received major surgery within the 4 weeks prior to starting the trial.
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
Any major surgery within the last four weeks.
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Major surgery within the last 4 weeks; minor surgery within the last 2 weeks
Major surgery within 14 days prior to study entry
Major surgery 21 days or less prior to starting study drug or has not recovered from adverse effects from such procedure.
Major surgery within 14 days prior to start of study treatment
Major surgery within 4 weeks prior to inclusion
Patients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
At least 4 weeks beyond treatment (chemotherapy, immunotherapy and/or radiation therapy) or major surgery and recovered from all acute toxicities
Major surgery or radiation ? 2 weeks prior to starting study treatment or who have not recovered from side effects of surgery or radiation
Patients who have had major injuries and/or surgery within the past 4 weeks (< 28 days) prior to registration with incomplete wound healing and/or planned surgery while the patient is on study treatment
At least 4 weeks must have elapsed from major surgery or radiation therapy prior to randomization
Major surgery within 28 days prior to the first study treatment. Participants must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before the first dose of study treatment
Major surgery (requiring general anesthesia) within 14 days before the first dose of study\r\ndrug or a scheduled surgery during study period
Major surgery within 12 weeks before the first dose of study treatment; complete wound healing from major surgery must have occurred 1 month before the first dose of study treatment; minor surgery (including uncomplicated tooth extractions) within 28 days before the first dose of study treatment with complete wound healing at least 10 days before the first dose of study treatment; subjects with clinically relevant ongoing complications from prior surgery are not eligible
At least 4 weeks have elapsed since the completion of major surgery, and the patient has fully recovered from this surgery and any post-surgical complications
Major surgery (as defined by the investigator) within the 28 days prior to day 1 of protocol therapy
Major surgery within 4 weeks of first dose of study drug
Patients must be at least 2 weeks from major surgery, radiation therapy, participation in other investigational trials and must have recovered from clinically significant toxicities of these prior treatments
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
Subjects who have had major surgery within 2 weeks prior to first dose of drug
At least 4 weeks must have elapsed since the last chemotherapy, radiotherapy or major surgery
Patient who has undergone major surgery =< 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedure; note: core needle biopsy, diagnostic tonsillectomy or excisional lymph node biopsy do not constitute major surgery
Major surgery within 4 weeks prior to day 1 of the study or who have not recovered from prior surgery
Prior major surgery =< 3 weeks before study drug or not recovered from side effects of such procedure
Major surgery within 28 days prior to first study treatment.
Major surgery within 28 days of C1D1
Major surgery within four weeks before first IMP administration.
Participants who have undergone major systemic surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery within 4 weeks of registration
Major thoracic or abdominal surgery from which the patient has not yet recovered.
Investigational agent, anticancer therapy, or major surgery within 14 days (2 weeks) prior to C1D1
Planned major surgery during the study
Major surgery within 4 weeks before randomization
Major surgery within 28 days of the first dose of study drug
Planned major surgery during the study or within 4 weeks of Cycle 1, Day 1
Major surgery within 1 month prior to enrollment.
Patients must be at least 4 weeks from radiation therapy or major surgery and have recovered from prior toxicities
Major surgery within 21 days of starting protocol treatment
Major surgery within 8 weeks of study enrollment or planned major surgery during study and up to 6 months after discontinuation of study drug
Major surgery =< 3 weeks prior to registration or failure to adequately recover from surgery
Major surgery within prior 4 weeks (the surgical incision should be fully healed prior to drug administration)
Patients who have had major surgery or trauma within 28 days prior to entering the study; patients must have recovered from any effects of any major surgery and surgical wound should have healed prior to starting treatment
Major surgery within 2 weeks before day 1
Patients who are less than 4 weeks post-operative (op) after major surgery
No planned major surgery
Planned major surgery
Recent major surgery (within the past 14 days)
Major surgery without full recovery or major surgery within 3 weeks of Screening.
Major surgery =< 4 weeks prior to registration or have not recovered from side effects of such therapy
Ibrutinib must be discontinued 7 days before (when possible) until 7 days after major surgery, and 3 days before (when possible) until 3 days after minor surgery; thus, patients to be enrolled on an ibrutinib trial must have completed major surgery > 7 days before initiating treatment, and/or must have completed minor surgery > 3 days before initiating treatment
Major surgery within 4 weeks of first dose of study drug
Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery
Major surgery =< 14 days prior to study registration
Minimum of four weeks since any major surgery, completion of radiation
Patients who have undergone major surgery within 4 weeks prior to study enrollment
Patients less than 4 weeks post major surgery
Subjects who have had a major surgery or significant trauma within 4 weeks before the start of study treatment
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 2 weeks of first dose of study drug; patients must have recovered from the effects of any surgery performed greater than 2 weeks previously
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 2 weeks of first dose of study drug; patients must have recovered from the effects of any surgery performed greater than 2 weeks prior
Major surgery within four weeks before day 1
Subject has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects
Major surgery within 6 weeks prior to study day 1 (subjects must have completely recovered from any previous surgery prior to study day 1)
Patients who have undergone major surgery =< 4 weeks prior to starting study treatment or who have not recovered from side effects of such procedure
Patients who have undergone major surgery within 4 weeks prior to starting the study treatment
Major surgery within 14 days before enrollment
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Prior major surgery or radiation therapy within 14 days of initiation of treatment
At least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy); there is no delay in treatment for minor procedures (e.g., tumor core biopsy)
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery
Patients who have undergone major surgery, excluding diagnostic biopsy, within 30 days (to allow for full recovery) prior to registration
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have had major surgery without full recovery or major surgery within three weeks of the start of vaccine treatment
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery, other than diagnostic surgery, occurring 4 weeks prior to study entry; splenectomy will not be considered an exclusionary major surgery
Patients may have received prior surgery (e.g., pleurectomy, pleurodeisis) provided at least 28 days have elapsed since surgery (thoracic or other major surgeries) and patients have recovered from all associated toxicities at the time of registration; there must be no anticipated need for major surgical procedures during protocol treatment
Major surgery within 4 weeks prior to the screening visit
Patients must not have had major surgery within 28 days prior to registration or be scheduled for surgery during the projected course of protocol treatment; tumor biopsy is allowed
Subject has had major surgery within 4 weeks prior to the first study dose.
Has had major surgery within 2 weeks prior to enrollment
Patients may have received prior surgery; for all major surgeries, at least 14 days must have elapsed since completion and patient must have recovered from all major side effects of surgery per investigators assessment
Major surgery within 4 weeks prior to screening.
Major surgery within 21 days of study treatment; minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgery
The participant underwent major surgery within 28 days.
Major surgery within 4 weeks prior to randomization
Participants with major surgery in the 4 weeks prior to randomization (Video-assisted thoracoscopic surgery (VATS) and/or mediastinoscopy is not considered major surgery).
Major surgery within 21 days of study treatment; minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgery
Has had major surgery to liver or other site within 4 weeks prior to the first dose of study drug.
Major surgery within 4 weeks prior to first dose of study drug.
Major surgery within 4 weeks prior to study day 1 (patients must have recovered completely from any previous surgery prior to study day 1).
The patient has undergone major surgery within 28 days prior to first dose of protocol therapy
had major surgery within 14 days prior to randomization
Major surgery for any reason, except diagnostic biopsy, within 4 weeks of enrolment and/or if the subject has not fully recovered from the surgery within 4 weeks of enrolment
Patients who have undergone major surgery =< 4 weeks prior to starting study treatment, who have not recovered from side effects of such procedure
PRIOR/CONCURRENT THERAPY CRITERIA: Patients must not have had a major surgery within 28 days prior to registration; patients must have recovered from any adverse effects of prior surgery to the satisfaction of the treating physician; biopsies and central IV access placement are not considered major surgery
Major surgery within 4 weeks before first dose of study drug.
Major surgery within 4 weeks before first dose of study drug.
Subject has had major surgery, other than diagnostic surgery, within 4 weeks prior to treatment in study.
major surgery within 4 weeks of first dose of study drug
Major surgery within 21 days of starting protocol treatment
Subject has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects
Major surgery within 4 weeks before randomization;
Major surgery </= 4 weeks before study treatment
Major surgery or radiation therapy < 4 weeks of starting study treatment
Major surgery within 2 weeks prior to registration; patients must have recovered from any effects of any major surgery
Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
Major surgery within 28 days prior to randomization
Major surgery within 2 weeks prior to randomization.
Major surgery or trauma within four weeks before enrollment.
Major surgery within 4 weeks prior to first dose
Major surgery (as defined by the investigator) within the 28 days prior to the first dose of study treatment
Major surgery within 2 weeks prior to the first dose of lenvatinib.
Scheduled for major surgery during the study.
Major surgery less than 1 month before start of the study
Major surgery within 28 days before randomization
Major surgery <4 weeks or radiation therapy <2 weeks of patient registration.
Major surgery within 28 days prior to first dose of study drug
Have had any major surgery within four weeks of enrollment.
Has had major surgery within 3 weeks prior to enrollment NOTE: Minor surgery (e.g., minor biopsy, central venous catheter placement) is permitted within 3 weeks prior to enrollment.
Has had major surgery within 4 weeks, received radiation therapy within 2 weeks prior to randomization, or has not recovered (i.e., ? Grade 1 or at baseline) from AEs due to prior treatment.
Prior chemotherapy, radiotherapy, biological cancer therapy or major surgery within 28 days prior to enrollment
Subject had a major surgery within 4 weeks prior to day 1.
Patient has had major surgery =< 14 days prior to registration or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Patients who have had major surgery within one month (28 days) prior to registration are not eligible
Major surgery within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
Major injuries or surgery within the 4 weeks prior to initiation of therapy with incomplete wound healing or planned surgery during the on-study treatment period
Major surgery within 4 weeks prior to enrollment
Major surgery within 28 days before randomisation.
Major surgery for any reason, except diagnostic biopsy, within 4 weeks and/or if the subject has not fully recovered from the surgery within 4 weeks
Major surgery within 4 weeks of randomization;
Major surgery requiring the use of general anesthetic within 4 weeks of study enrollment
Major surgery within 4 weeks of the first dose of study drug
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Patients that have undergone major surgery within the last 4 weeks before enrollment;
Have an elective or a planned major surgery during the course of the trial or has undergone major surgery within 28 days prior to enrollment.
Surgery within 4 weeks prior to first dose
Major surgery within 28 days (four weeks) prior to registration.
Major surgery less than 1 month before the start of the study
Subjects having undergone a major surgery within the last 6 weeks
Are at least 4 weeks from major surgery and recovered.
Major surgery, other than diagnostic surgery (e.g., surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to first dose.
Major surgery within 4 weeks prior to Day 1 study
No major surgery within 28 days prior to treatment; no minor surgery within 5 days prior to treatment
Major surgery within 4 weeks of first dose of study drug
No history of major surgery =< 14 days prior to registration
Subject has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis or an aborted Whipple), within 28 days prior to day 1 of treatment in this study
Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within 3 weeks of the first dose of study medication
Major surgery without full recovery or major surgery within 3 weeks of Screening.
Major surgery ? 2 weeks prior to starting study drug or still recovering from post operative side effects.
Major surgery within the previous 4 weeks
Have received prior chemotherapy, other investigational therapy, or major surgery within 4 weeks of Day 1;
Patients who have undergone major surgery within 14 days
Major surgery, within 28 days of first dose of study drug
Severe infection or major surgery within 4 weeks, or oral or IV antibiotics treatment within 2 weeks prior to enrollment
Major surgery within 4 weeks before the first dose of study drug.
Major surgery within 30 days prior to enrollment.
Major surgery within 4 weeks of enrollment
Major surgery within 14 days before first dose or a scheduled surgery during study period; insertion of a venous access device (eg, catheter, port) is not considered major surgery.
Known need for major surgery within 14 days of the first dose of Ribociclib. Gastrostomy, insertion of a G tube, Ventriculo-peritoneal shunt, endoscopic ventriculostomy and central venous access are NOT considered major surgery.
Major surgery performed < 28 days from treatment start
Major surgery within 4 weeks of starting trial
Major surgery within 28 days of study drug
Have had major surgery (excluding biopsy) < 28 days of the initial dose of study drug.
Major surgery within 4 weeks of first dose of study drug.
Major surgery
Major surgery within 4 weeks of study treatment
Major surgery within 4 weeks of first dose of study drug
Major surgery =< 2 weeks prior to starting a study drug or who have not recovered from side effects of such therapy
Have undergone major surgery or received any investigational therapy in the 4 weeks prior to study entry.
Major surgery within 4 weeks
Subject has undergone major surgery, other than diagnostic surgery (i.e.--surgery done to obtain a biopsy for diagnosis or an aborted Whipple), within 28 days prior to day 1 of treatment in this study
Has had major surgery within 21 days before cycle 1 day 1
Patients with major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedure
Have had major surgery within 14 days prior to randomization
Patients who have undergone major surgery within 1 month prior to screening.
Received major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK2879552 administration.
Patients who:\r\n* Have had a major surgery or significant traumatic injury within 4 weeks from day 1 of study drug\r\n* Have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or\r\n* Are anticipated to require major surgery during the course of the study
Recent major surgery
Major surgery within 14 days before first dose of study drug
Any major surgery within 4 weeks or a diagnostic procedure (e.g. incision, needle biopsy) within 1 day of study drug administration
Major surgery within six weeks or open biopsy within 14 days before drug infusion.
Plan for any major surgery during treatment period.
Major surgery or any anti-cancer therapy within 2 weeks of randomization
Patients may not have had major surgery within 10 days of enrollment, or minor surgery within 7 days of enrollment; examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint; the decision about whether a surgery is major or minor can be made at the discretion of the treating physician
Major surgery within 3 weeks prior to randomization or scheduled for surgery during the study
Major surgery =< 4 weeks prior to registration; minor surgery =< 2 weeks prior to registration; insertion of a vascular access device is not considered major or minor surgery; subjects must have recovered from all surgery related toxicities to =< grade 1 or to baseline if subject started with > grade 1 toxicity, not otherwise violating the above inclusion criteria
Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgery
Patients must be at least 4 weeks from major surgery and must be fully recovered
Have had a major surgery or significant trauma within 4 weeks of enrollment (Part 1) or randomization (Part 2).
Major surgery within 4 weeks of study treatment
Major surgery within 28 days of study day 1
Systemic cytotoxic chemotherapy, antineoplastic biologic therapy, or major surgery within 21 days of the first dose of trial medication
Have a planned major surgery.
Major surgery within 2 weeks of the first dose of study treatment
Major surgery within 28 days before Cycle 1 Day 1
Subject has had major surgery within 4 weeks prior to the first study dose.
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered a major surgery)
Any major surgery =< 28 days prior to the initiation of investigational products
Major surgery ? 2 weeks and recovered from any clinically significant effects of recent surgery.
Major surgery within 2 weeks of the first dose of study drug (minimally invasive procedures such as bronchoscopy, tumor biopsy, insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary)
Trauma or major surgery within 4 weeks of first study drug administration
Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery
Patients had a major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedure
Major surgery, other than diagnostic surgery, within 2 weeks
Patients who have undergone major surgery =< 4 weeks prior to registration or have not recovered from side effects of such procedure are not eligible for participation
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery).
Major surgery within 4 weeks of enrollment
Major surgery within 4 weeks of starting treatment.
Major injuries and/or surgery within the past 4 weeks prior to start of study treatment with incomplete wound healing and/or planned surgery during the on-treatment study period
Major surgery within 4 weeks prior to entry to the study (excluding placement of vascular access), or minor surgery (excluding tumor biopsies) within 14 days of first dose of study treatment
Subjects enrolling on the ibrutinib arm must not have had major surgery within 14 days, or minor surgery within 7 days
Patient has had major surgery or a wound that has not fully healed within 4 weeks of starting study drugs
Major surgery within 14 days prior to enrollment
Major surgery within 4 weeks of the start of study treatment, without complete recovery
Major surgery within 4 weeks prior to enrollment (day 1 visit)
Major surgery =< 4 weeks prior to registration of the study or who have not recovered from prior surgery regardless of time since surgery
Major surgery within 4 weeks of first dose of study drug
Major surgery within 4 weeks of starting the study treatment
Patients may have received prior surgery (e.g., pleurectomy) provided that at least 28 days have elapsed since surgery (thoracic or other major surgeries) and patients have recovered (i.e., =< grade 1 or at baseline) from all associated toxicities at the time of registration; there must be no anticipated need for major surgical procedures during protocol treatment
Major surgery within 4 weeks of the start of study treatment defined as those surgeries that require general anesthesia; insertion of a vascular access device is NOT considered major surgery
Major surgery within 2 weeks of study drug administration
Patients who have undergone major surgery within 7 days or minor surgery within 3 days of first dose of study drug
Major surgery (within 4 weeks prior to the start of cycle 1), other than for diagnosis
Any major surgery within the last 3 weeks
Major surgery within 2 weeks of first dose of study drug; patients must have recovered from the effects of any surgery performed greater than 2 weeks previously
Major surgery within 30 days before study entry.
The participant has undergone major surgery or received anti-cancer monoclonal antibody therapy in the 30-days prior to study enrollment.
Major surgery within 4 weeks of initiation of therapy
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects (tumor biopsy is not considered as major surgery)
Major surgery within 14 days before enrollment
Has had major surgery or significant traumatic injury within 4 weeks of study registration. Subjects must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy. A diagnostic or research biopsy does not exclude subjects from enrollment. Placement of a vascular access device such as a Port-A-Cath is not considered major surgery
Participants who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of the surgery
Major surgery within 30 days prior to start of study drug
Major surgery =< 4 weeks prior to starting study regimen or who have not recovered from surgery
Had major surgery within 4 weeks of first dose of study drug
Subjects who had major surgery within 4 weeks of the first day of study drug.
Patient underwent major systemic surgery =< 2 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Major surgery within 4 weeks of the first dose of study drug.
Any major surgery or open biopsy completed >= 4 weeks prior to randomization
Major surgery within 4 weeks prior to first study drug administration
Patient who has undergone major surgery =< 4 weeks prior to starting study treatment or who has not recovered from side effects of such procedure
Major surgery within 6 weeks prior to study day 1 (subjects must have completely recovered from any previous surgery prior to study day 1)
Any major surgery or extensive radiotherapy within 28 days prior to screening
Major surgery within 4 weeks of initiation of therapy
Major surgery or radiation therapy within 30 days of screening visit
Prior systemic chemotherapy, radiation therapy or major surgery =< 30 days prior to registration
Patients with recent major surgery within 14 days prior to cycle 1, day 1
Major surgery (within 4 weeks prior to the start of cycle 1), except for procedures that are performed for diagnostic purposes
Major surgery (as defined by the investigator) within 4 weeks prior to first dose of MEDI6383 or still recovering from prior surgery. Local surgery of isolated lesions for palliative intent is acceptable
Patients must not have received chemotherapy, radiation therapy, or undergone major surgery within 4 weeks prior to enrollment
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients who have had major surgery within 28 days prior to entry into the study or be recovering from any effects of surgery; patients who have had minor surgery within 2 weeks prior to entry into the study
Major surgery within 30 days prior to start of study drug
Major surgery within four weeks before day -7
Major surgery within 14 days before randomization.
Major surgery within three weeks before cycle 1 day 1
Any major surgery, chemotherapy or immunotherapy within the last 21 days
Subjects that have undergone major surgery within 4 weeks prior to the first dose of study drug are not eligible
At least 4 weeks since major unrelated surgery, with full recovery
Major surgery or radiotherapy within 14 days of randomization.
Major surgery =< 28 days prior to registration
Major surgery within four weeks before initiation of therapy
Major surgery within 14 days before enrollment
At least 4 weeks must have elapsed from major surgery prior to starting study drug
No major surgery within 2 weeks of starting study treatment
Surgery: at least 2 weeks since undergoing any major surgery and must be recovered from effects of surgery
Major surgery within 21 days prior to the first day of treatment
Major surgery within 28 days prior to the first dose of study medication
Received monoclonal antibodies or had major surgery within 30 days of the first dose of brigatinib (Day 1, Cycle 1).
Major surgery within 2 weeks before day 1
At least 4 weeks must have elapsed from major surgery
Patients who have undergone major surgery =< 2 weeks prior to registration to study or who have not recovered from the side-effects of surgery
Prior major surgery less than 4 weeks prior to the start of the study;
No major surgery within 4 weeks prior to study entry
Has had major surgery within 28 days prior to enrollment
Patients who have undergone major surgery within 2 weeks prior to study enrollment or who have not recovered from a major surgery
No major surgery within the last 4 weeks (28 days) of first dose of study drug or minor surgery within 3 days of first dose of study drug
Patients who have undergone major surgery =< 4 weeks prior to registration or who have not recovered from side effects of such procedure are not eligible for participation
Major thoracic or abdominal surgery from which the patient has not yet recovered.
Major surgery within 4 weeks before first dose of study drug.
Major surgery within 4 weeks of registration
Major surgery or radiation therapy within 4 weeks of cycle 1, day 1
Major surgery within 4 weeks prior to first dose.
No major surgery within 14 days and minor surgery within 7 days prior to cycle 1 day 1
Major surgery within the 28 days preceding the first dose of study drug
COHORT A: Major surgery within 4 weeks of enrollment (week 1 visit)
COHORT B: Major surgery within 4 weeks of enrollment (week 1 visit)
Major surgery within 30 days prior to the first dose of study treatment
Major surgery or invasive intervention within 4 weeks prior to randomization
Major surgery, chemotherapy, hormonal or immunologic therapy =< 3 weeks prior to registration
Major surgery within 2 weeks of starting study treatment and patients must have recovered from any effects of any major surgery.
Participants who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of the surgery
Any major surgery within the last 4 weeks
Subject has had major surgery within 4 weeks prior to the first study dose.
Subjects who have had major surgery within 4 weeks prior to entering the study
Prior major surgery less than 14 days prior to enrollment. Any surgery-related AE(s) must have resolved prior to enrollment
Major surgery within 3 weeks prior to first dose
Major surgery within 2 weeks of study treatment initiation and patients must have recovered from any effects of any major surgery.
Major surgery within 2 weeks of first dose of lenvatinib
Major surgery within 1 month prior to enrollment.
Major surgery within 4 weeks prior to study enrollment.
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery within 3 weeks prior to first dose
Patients who are within 4 weeks of major surgery or within 2 weeks of minor surgery
No major surgery within 4 weeks prior to enrollment
At least 4 weeks must have elapsed from major surgery or radiation therapy prior to randomization
Major surgery within 21 days prior to signing consent
Major surgery or radiation therapy within 4 weeks of enrollment
A minimum of 4 weeks from any major surgery prior to start of study drug
PART B: Patients who have had major surgery within 28 days prior to entering the study or those who have not recovered from adverse events > grade 1 relating to the surgery
Patients must be > 4 weeks from any major surgery
Major surgery within 4 weeks or minor surgery within 7 days of the first day of study drug dosing
Major surgery within 3 weeks prior to first dose
Major surgery within 3 weeks before the first dose of study drug.
Major surgery < 4 weeks or minor surgery (e.g. talc pleurodesis, excisional biopsy, etc) < 2 weeks prior to the first day of study defined treatment
Major surgery within 4 weeks prior to enrollment (day 1 visit)
Patients who have undergone major surgery =< 4 weeks prior to starting study treatment, who have not recovered from side effects of such procedure
Major surgery within 4 weeks of random assignment
Participants who have undergone any major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery or radiotherapy within 14 days before randomization
Major surgery within 30 days prior to start of study drug
Patients must be at least 2 weeks from major surgery, radiation therapy, participation in other investigational trials and must have recovered from clinically significant toxicities of these prior treatments
Major surgery within 4 weeks prior to entering the study
Patients who have had major surgery or radiation therapy within 21 days of starting treatment
Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery within 3 weeks prior to first dose
Major surgery =< 4 weeks prior to registration of the study or who have not recovered from prior surgery
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Recovery from any major or minor surgeries; patient must be 4 weeks post-major surgery and 2 weeks post-minor surgery
Major surgery within the last 4 weeks; minor surgery within the last 2 weeks
Major surgery < 4 weeks from the start of treatment
Participants who have undergone any major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Surgery within 4 weeks prior to first dose
Major surgery within 4 weeks prior to first dose
Surgery within 4 weeks prior to first dose.
Patients who have had any major surgery within 21 days prior to enrollment
Any major surgery, chemotherapy or immunotherapy within the last 21 days (limited palliative radiation is allowed ? 2 weeks);
Patients who have undergone major surgery or radiotherapy ? 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure;
Major surgery or radiation therapy within four weeks of the first dose of ARQ 087
Major surgery within 4 weeks before first day of study drug dosing
Major surgery within 14 days before the first dose of study drug
Major surgery within 4 weeks prior to entering the study
Major surgery within 4 weeks of registration is prohibited
Any major surgery or radiation therapy within four weeks.
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery or radiation therapy within 4 weeks of enrollment (day 1 visit)
Major surgery or radiation therapy within 4 weeks before first study drug administration.
Patients with major surgery within 28 days prior to treatment
Major surgery within 28 days prior to enrollment or still recovering from prior surgery
Patients who have not recovered from the side effects of any major surgery
Patients that may require major surgery during the course of the study
Patients with major surgery less than 3 months prior to start study drug or who have still side effects of such therapy.
Major surgery within 4 weeks
Major surgery within 4 weeks of Study Day 1
Patients must not have received chemotherapy, radiation therapy, or undergone major surgery within 4 weeks prior to enrollment
Major surgery within 3 weeks prior to day 1 of study treatment from which the patient has not completely recovered
Patients with major surgery within 30 days prior to entering the study
Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery
Major surgery or radiation therapy < 4 weeks of starting study treatment
Major surgery within 14 days before randomization.
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
>= 2 weeks since major surgery
Major surgery, other than diagnostic surgery, within 2 weeks
Patients should have completed any major surgery or open biopsy >= 4 weeks from start date of chemotherapy; patients must have completed any minor surgery or core biopsy >= 1 week prior to first dose of bevacizumab; (insertion of a vascular access device is not considered major or minor surgery)
Prior treatment (major surgery, radiation therapy, chemotherapy, or other investigational drugs) received within 28 days before randomization.
Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery
Patient has had major surgery within the last 3 weeks
Major surgery within 4 weeks of study randomisation.
No major surgery or radiation in the prior 4 weeks prior to enrollment
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patient has undergone a major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis without removal of an organ) within four weeks prior to day 1 of treatment on this study
Patients having undergone major surgery less than 4 weeks prior to enrollment or have not fully recovered from prior surgery
Major surgery within 28 days of Day 1
Major surgery within 14 days before study registration
Major surgery within 4 weeks prior to day 1 of the study or who have not recovered from prior surgery
Major surgery within 28 days prior to registration
Major surgery within 14 days and minor surgery within 7 days prior to cycle 1 day 1
Recent major surgery (within 4 weeks prior to start of Cycle 1), other than for diagnosis
Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study
Have undergone major surgery =< 2 weeks prior to starting BKM120 or BYL719 or have not recovered from side effects of such therapy
Minimum of four weeks since any major surgery or since completion of radiation (patients should have adequately recovered from the acute toxicities of any prior therapy)
Patients who have undergone major surgery within 4 weeks prior to study enrollment (tracheotomy, feeding tube or vascular access catheter placement and interventional procedures such as bronchoscopy, upper gastrointestinal [GI] endoscopy or colonoscopy are not considered major surgery)
Major surgery =< 4 weeks prior to registration or have not recovered from side effects of such therapy
Underwent major surgery within 14 days prior to first dose of ponatinib
Patients with major surgery within 30 days prior to entering the study
Prior major surgery (defined as requiring general anesthesia) or trauma within 28 days prior to first dose of study drug, and/or not recovered from effects of that surgery, and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major), or patients that may require surgery during the course of the study
EXPANSION COHORT ONLY: Prior major surgery (defined as requiring general anesthesia) or trauma within 28 days prior to first dose of study drug, and/or not recovered from effects of that surgery, and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major), or patients that may require surgery during the course of the study
Major surgery within 7 days of enrollment
Major surgery within three months prior to Day 1 of study or who have not recovered adequately from prior surgery.
Any major surgery or extensive radiotherapy within 21 days of starting treatment on protocol
Has had major surgery within 3 weeks prior to receiving the first dose of study treatment or has not recovered adequately from toxicity and/or complications from an intervention prior to receiving the first dose of study treatment.
At least 4 weeks must have elapsed from major surgery
Major surgery within 2 weeks of starting study treatment, and subjects must have recovered from any effects of any major surgery;
Major surgery planned within 4 weeks of the first dose of study drug
Major surgery within 3 weeks prior to first dose
Major surgery within 3 weeks prior to first study drug administration.
Major surgery within 14 days prior to the first dose of study drug
Major or minor surgery < 28 and <14 days from the start of treatment, respectively;
Any major surgery within 4 weeks of starting treatment on protocol
Major surgery or trauma occurring within 28 days of starting the trial
Recent major surgery (within 4 weeks), other than for diagnosis
Major surgery within 4 weeks before randomization
Major surgery, chemotherapy, radiotherapy, investigational agents or other cancer therapy within 1 week of treatment day 1
Major surgery within 28 days
Major surgery within 4 weeks (or within 2 weeks following consultation with and approval of Medical Monitor)
Major surgery within 30 days of study medication
Major surgery within 21 days prior to the first dose of ABBV-838
Major surgery within 28 days of the first dose of study treatment
Patients who have had major surgery must be fully recovered and >= 4 weeks post-operative prior to enrolling on study
Has had major surgery (requiring at least a 3 day hospital stay) in the past 28 days
Major surgery within 4 weeks of screening
Major surgery within 4 weeks before the start of study therapy.
Major surgery or irradiation within two weeks
Patients who have undergone major surgery =< 4 weeks prior to starting treatment or who have not recovered from side effects of such therapy
Major surgery or irradiation within two weeks
Major surgery within 4 weeks before the start of study therapy;
Major surgery within 4 weeks or minor surgery within 2 weeks prior the first dose of study medication
Elective or a planned major surgery while on study treatment
Major surgery within 28 days prior to the first dose of study drug.
Undergone major surgery within 30 days prior to randomization
Major surgery: ?2 weeks Other protocol defined inclusion/exclusion may apply.
Major surgery or a wound that has not fully healed within 4 weeks of enrollment
Major surgery within 4 weeks prior to entry
Major surgery within 4 weeks of enrollment
The participant has a history of major surgery or treatment other cancer therapy within 2-6 weeks before starting the study
Major surgery within 4 weeks of 1st dose of study drug
Major surgery within 2 weeks
Major surgery within 4 weeks (less than 28 days) prior to C1D1
Major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
Major surgery within 4 weeks or minor surgery within 2 weeks prior to the first dose of study medication
Major surgery within 4 weeks prior to C1D1
Major surgery within 14 days before enrollment
Major surgery within 4 weeks prior to Day 1 visit.
Major surgery within 28 days of study day 1
Major surgery within 4 weeks from cycle # 1
Major surgery within 28 days prior to the first dose of study drug.
Major surgery within 4 weeks of first dose of study drug.
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery within 14 days before enrollment
Major surgery within 2 weeks before cycle 1 day 1
Major surgery, chemotherapy, radiation therapy or other cancer therapy within 3 weeks of treatment day 1
Subject has undergone major surgery for any reason, other than diagnostic surgery (ie, surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to Cycle 1 Day 1 of treatment in this study.
Major surgery within 4 weeks prior to day 1 of the study or who have not recovered from prior surgery
Major surgery within 6 weeks prior to Baseline. The subject must have recovered from surgery and be without current complications of infection or dehiscence.
Major surgery within 14 days before enrollment
Major surgery within 4 weeks of C1D1
Patients may not begin protocol therapy within 7 days of major surgery or within 3 days of minor surgery
Major surgery within 28 days of first dose of study drug
Major surgery or radiation within 4 weeks prior to 1st dose
Major surgery within 14 days before enrollment
Major surgery requiring general anesthesia within 21 days or minor surgery within 14 days of study enrollment; subjects must have recovered from surgery related toxicities
Major surgery or anti-cancer therapy within 4 weeks of study treatment start.
9. Major surgery within 28 days prior to the first dose of study drug.
Major surgery, other than diagnostic surgery, within 4 weeks prior to Cycle 1 Day 1, without complete recovery
Patients that have had major surgery =< 3 weeks or minor surgery (e.g. talc pleurodesis, excisional biopsy, etc) =< 1 week prior to the first day of study defined treatment
Patient has undergone major surgery, other than diagnostic surgery (i.e.--surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to day 1 of treatment in this study
Major surgery within 4 weeks
Patient has undergone major surgery, other than diagnostic surgery (i.e. surgery done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks prior to day 1 of treatment in this study
Major trauma or surgery w/in prior 4 weeks
Major surgery within 4 weeks of the start of study treatment, without complete recovery
Major surgery within 2 weeks prior to study entry, except for line placement or biopsy procedure.
Major surgery within the last 2 weeks
Major surgery other than diagnostic surgery =< 4 weeks
Major surgery within 28 days
Patient had major surgery within 28 days prior to starting study drug or has not recovered from major side effects of the surgery
At least 3 weeks from major surgery with full recovery
Major surgery within 1 month prior to enrollment
Scheduled for major surgery during the study.
Major surgery within 4 weeks prior to study enrollment
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Any major surgery =< 28 days prior to registration
Major surgery within 2 weeks of first dose of study drug. Patients must have recovered from the effects of any surgery performed greater than 2 weeks previously.
At least 4 weeks have elapsed since the completion of major surgery, and the patient has fully recovered from this surgery and any post-surgical complications.
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects.
Have undergone major surgery within 28 days prior to receiving study drugs.
Major surgery within 4 weeks prior to day 1
Major surgery within 14 days before day 1.
Major surgery ?4 weeks before first dose of study drug, or incomplete recovery from a prior major surgical procedure
Patients who have had major surgery within 2 weeks prior to enrollment are not eligible; procedures such as placement of a central vascular catheter, or limited tumor biopsy, are not considered major surgery
Severe infection or major surgery within 4 weeks prior to randomization
Major surgery ? 2 weeks or radiotherapy ? 4 weeks prior to planned start of study drug or patient has not recovered from major side effects.
Major surgery within 4 weeks prior to first dose
Major surgery, excluding laparoscopy, within 4 weeks of the start of study treatment, without complete recovery
Major surgery, chemotherapy, investigational agent, or radiation within 30 days of Day
Major surgery within 28 days before Cycle 1 Day 1
Major surgery within 28 days of study day 1
No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment
Less than 3 weeks between major surgery and planned start of study treatment; major incisions must have healed
Patients must be at least 4 weeks from major surgery and have fully recovered from any effects of surgery, and be free of significant detectable infection prior to registration
Major surgery within 4 weeks of initiation of study drug
Major surgery =< 2 weeks prior to starting a study drug or who have not recovered from side effects of such therapy
Major surgery within six weeks or open biopsy within 14 days before drug infusion.
Plan for any major surgery during treatment period.
Prior major surgery or radiation therapy within 4 weeks of enrollment;
Subject has had major surgery within 4 weeks prior to the first study dose.
Major surgery within 4 weeks prior to entry to the study (excluding placement of vascular access), or minor surgery within 2 weeks of entry into the study and from which the patient has not yet recovered
Major surgery within 3 weeks before day 1
Major surgery within 2 weeks before day 1
Major surgery within 14 days prior to starting Investigational Product or has not recovered from major side effects.
Any major surgery (e.g. requiring general anesthesia).
Major surgery ? 21 days from beginning of study drug
Ibrutinib must be discontinued 7 days before (when possible) until 7 days after major surgery, and 3 days before (when possible) until 3 days after minor surgery; thus, patients to be enrolled on an ibrutinib trial must have completed major surgery within 4 weeks before initiating treatment, and/or must have completed minor surgery > 3 days before initiating treatment
Major surgery within 14 days before the first dose of study drug.
Major surgery (as judged by the investigator) within 4 weeks
Recent major surgery (within 6 weeks before the start of Cycle 1 Day 1), other than for diagnosis
Any major surgery within 4 weeks of study randomization.
Major surgery within 4 weeks prior to randomization.
Prior major surgery from which the subject has not yet recovered to baseline;
14 days must have elapsed since prior major surgery
Major surgery within 2 weeks before the first dose of either study drug
Major surgery, radiation therapy or systemic anti-cancer therapy within 4 weeks of starting study treatment
Major surgery within 14 days before the first dose of study treatment.
Patients who have had major surgery within 4 weeks of enrollment
Patients who have had major surgery within 3 weeks prior to enrollment are not eligible; procedures such as placement of a central vascular catheter, or limited tumor biopsy, are not considered major surgery
Patients who have had major surgery within 14 days of study enrollment
Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of study treatment start
Major surgery within 28 days before the first dose of study drug
Major surgery within 4 weeks prior to first dose of ganetespib
Major surgery within 30 days prior to date of randomization.
Patients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
Major surgery within 21 days before Study Day 1;
Major surgery within 4 weeks prior to study day 1 Active infection Anti-coagulation therapy Concomitant treatment with potent CYP3A4 inducers
Major surgery, except diagnostic tumor biopsy, within 4 weeks of randomization.
Subject has had major surgery within 4 weeks prior to the first study dose.
Major surgery within 4 weeks, or minor surgery within 2 weeks prior to day 1 of cycle 1
Major surgery (as defined by the investigator) within 4 weeks prior to first dose of MEDI0680 (AMP-514) or still recovering from prior surgery
Be reasonably recovered from preceding major surgery as judged by the investigator or no major surgery within 4 weeks prior to the start of day 1 treatment
Anti-tumor therapy of any kind or major surgery within 4 weeks prior to Day 1.
Any major surgery or extensive radiotherapy within 21 days prior to randomization and crossover
Any major surgery within 4 weeks prior to day 1
Major surgery (excluding kyphoplasty) within 28 days prior to randomization
Major surgery, chemotherapy, investigational agent, or radiation within 30 days of Day 1
Major surgery (within 4 weeks prior to the start of Cycle 1), other than for diagnosis
Prior major surgery or trauma within 28 days before first dose of study drug
Major surgery within 14 days before the first dose of study drug
Major surgery or radiotherapy within 14 days before study drug administration
Major surgery or trauma within 4 weeks
Major surgery within 14 days before the first dose of study drug
Major surgery or significant traumatic injury within 4 weeks of randomization or patients that may require major surgery during the course of the study.
Major surgery within 21 days prior to first dose
Minimum of 21 days have elapsed since prior major surgery, with recovery from any adverse events.
Major surgery within 21 days prior to randomization
Major surgery within 4 weeks prior to IP administration
The subject had had major surgery within 28 days prior to the first dose of ABT-414.
Major surgery within 30 days
Major surgery =< 14 days prior to registration
Major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Major surgery within 4 weeks of study enrollment
Fully recovered from any prior surgery and no major surgery within 4 weeks of initiating treatment, except for gamma knife which can take place within 2 weeks. Surgery for placement of vascular access devices is acceptable.
Major surgery within 4 weeks before start of study treatment, without complete recovery
Major surgery within 21 days prior to first dose
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Subjects may not have any major surgery within 4 weeks
Previous major surgery within 28 days prior to enrolment
At least 4 weeks from prior major surgery or radiotherapy
Major surgery or significant trauma within 2 weeks prior to the first dose of study drug.
Major surgery within 4 weeks prior to entry into the study, or a surgical incision that is not fully healed
Recent major surgery within a minimum of 4 weeks prior to starting study treatment, with the exception of surgical placement for vascular access
Major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery
Major surgery within 3 weeks of starting the study or patient has not recovered from any effects of any major surgery
Major surgery within 21 days of study treatment; minor surgery within 2 weeks of study treatment; placement of vascular access device and biopsies allowed and is not considered major or minor surgery
Patients who have had a major surgery of significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Patients who have had major surgery within 4 weeks of initiation of study medication
Major surgery (excluding kyphoplasty) within 28 days prior to randomization.
Major surgery within 28 days prior to enrollment or still recovering from prior surgery
Patients with major surgery within 30 days prior to entering the study
Major surgery within four weeks of the first dose of ARQ 092
Major surgery or radiotherapy within 14 days before the first dose of study drug
Has major surgery or radiotherapy within 14 days before the first dose of study drug
Major surgery within 21 days prior to randomization.
Patients who have undergone major surgery =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Patients must be at least 4 weeks from major surgery and have fully recovered from any effects of surgery, and be free of significant detectable infection
Major surgery (i.e., the opening of a major body cavity, requiring the use of general anesthesia) within 4 weeks before enrollment; minor surgery (except for insertion of vascular access device) within 2 weeks before enrollment; or not yet recovered from the effects of the surgery.
Major surgery within 30 days of study day 1
Major surgery within 14 days of initiation of study drug treatment
The participant has undergone major surgery within 28 days prior to randomization.
Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study
Major surgery within 4 weeks of the start of study treatment, without complete recovery
Patients who have undergone major surgery =< 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
Elective or a planned major surgery
Major surgery within 21 days prior to randomization
The subject has had prior major surgery within 30 days prior to first dose of study drug
At least 4 weeks from prior major surgery or radiotherapy.
No major surgery within 28 days of study entry
Major injuries and/or surgery within the past ten days prior to start of study drug
Major surgery, radiotherapy, chemotherapy or investigational agents within four weeks of treatment day 1
Major surgery ? 28 days prior to enrollment.
Patients who have undergone major surgery ? 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
If a patient has had major surgery, the patient must be longer than four weeks post surgery and must have recovered from all toxicity prior to beginning protocol study
Major surgery or a wound that has not fully healed =< 4 weeks prior to registration
Major surgery or a wound that has not fully healed within 4 weeks of treatment
A history of gastrointestinal malabsorption or having undergone surgery requiring gastrointestinal anastomoses within four weeks of starting therapy or who have not recovered from major surgery within three weeks of starting therapy
Patients who have undergone any major surgery within 2 weeks prior to starting study drug or who have not adequately recovered from previous surgery
Radiotherapy or major surgery within 4 weeks
Major surgery within four weeks before cycle 1, day 1
Major surgery within preceding 8 weeks
Patient has had major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior to starting study treatment or has not recovered from side effects of such procedure; video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can receive study treatment >= 1 week after these procedures
Patients who have undergone major surgery =< 3 weeks prior to starting study drug or who have not recovered from side effects of such procedure
Have had prior major rectal surgery (except hemorrhoids).
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects
Not scheduled for any major surgery during the anticipated study period
Major surgery within 30 days prior to registration
Major surgery within the past 2 weeks.
Have reasonably recovered from preceding major surgery as judged by the investigator or have had no major surgery within 4 weeks prior to Day 1 treatment.
Major surgery within 14 days before the first dose of study drug or incomplete recovery from any complications from surgery.
Patients with major surgery within 28 days prior to treatment
Received major surgery (as defined by the Investigator), radiotherapy, or immunotherapy within 28 days of the first scheduled dose of MEDI7247.
Major surgery within 4 weeks prior to the start of the study;
Has not recovered from major surgery prior to starting study therapy
Major surgery within 28 days prior to enrollment.
Major surgery within 28 days prior to enrollment.
Major surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.
Major surgery performed within 3 weeks prior to the first dose of study drugs or scheduled for major surgery during the study
Major surgery or radiation therapy within 4 weeks from start of treatment
Major surgery or a wound that has not fully healed within 4 weeks of starting ibrutinib
Major surgery less than 4 weeks before the start of the study
Patient is planning major surgery within the next 6 months
>= 4 weeks since last major surgery and fully recovered
No major surgery within 2 weeks prior to signing of study enrollment
Recovered from major surgery within the last 6 months
Major surgery =< 28 days prior to registration
Scheduled for major surgery within the study period
Major surgery within 1 month of starting study program and patients must have recovered from any effects of major surgery
Uncontrolled major psychiatric disorders, such as major depression or psychosis
Major surgery within 4 weeks or till recovery to baseline functioning (per patient) whichever is shorter
Prior major surgery within 4 weeks of starting study drug administration
Major surgery, significant trauma, wide-field radiotherapy, or therapy with monoclonal antibodies within 4 weeks before the first dose of study drug
Trauma or major surgery within 4 weeks of first study drug administration
Major surgery within 28 days prior to first dose of study drug.
Major surgery within <=28 days prior to the first dose of ABBV-085.
Major surgery within 4 weeks of first dose of study drug
Major surgery within 4 weeks of first dose of study drug
Patients who have had major non-biopsy surgery in the last 20 days.
Have had major surgery within 30 days prior to the start of Day 1;
The patient must be recovered from a prior major surgery; the major surgery must be performed at least 4 weeks prior to consent date
Major surgery within four weeks before consent date
Patient underwent major systemic surgery =< 2 weeks prior to starting the trial treatment or who has not recovered from the side effects of such surgery, or who plan to have surgery within 2 weeks of the first dose of the study drug
Major surgery within the past 2 weeks
Undergoing major surgery
Major surgery within two weeks of study registration of which the patient has not recovered
Major surgery within 30 days of day 1 of trial
Patients who have had major surgery within 4 weeks of initiation of study medication
Major surgery or radiation treatment within 3 months
EXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Major surgery within 4 weeks of first dose of study drug
Participants with acute intercurrent illness or those who had major surgery within the preceding 4 weeks unless they have fully recovered
Major surgery within 14 days before enrollment
Patient has had major surgery within 14 days prior to enrollment
Patients may have received prior radiation therapy or major surgery; however, at least 21 days prior to treatment start must have elapsed since completion of radiation therapy or major surgery and patient must have recovered from all side effects at the time of randomization
Major surgery within 28 days before Cycle 1 Day 1
Any major surgery within the last four weeks.
Subjects who have undergone major surgery ? 2 weeks prior to starting study drugs.
Major surgery within 2 weeks
Major surgery within 14 days of starting study treatment and patients must have recovered from any effects of any major surgery
Surgery within 4 weeks prior to first dose
Major surgery ? 28 days prior to the date of Randomization; patient must have complete recovery from surgery
Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy
Patient must not have undergone major surgery or radiotherapy to the pelvis or abdomen within previous 4 weeks
Major surgery within 14 days prior to start of study treatment
No surgery in the last 2 weeks prior to study enrollment
Major surgery other than diagnostic surgery within 28 days
Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study drug treatment
Major surgery within 4 weeks prior to first dose of study treatment.
Subjects must not have had major surgery as determined by the PI within 4 weeks before the first dose of investigational agent.
Major surgery within 4 weeks prior to C1D1.
Had major surgery within 4 weeks before study drug treatment
Major surgery within four weeks prior to entry to the study (excluding placement of vascular access), or minor surgery (excluding tumor biopsies) within 14 days of first dose of study treatment
Major surgery within 4 weeks of first dose of study drug
History of severe trauma or major surgery within 4 weeks prior to the initiation of study drug administration.
Has had chemotherapy, radiation, biological cancer therapy or major surgery within 4 weeks prior to the first dose of study treatment
Major surgery within 28 days of first drug dose
Major surgery within 4 weeks of the start of study treatment, without complete recovery
Major surgery or other loco regional treatment within 4 weeks before the first dose of study drug or radionuclide treatment within 8 weeks
A minimum of 4 weeks from any major surgery prior to enrollment; coincident standard of care surgery with the research biopsy is permitted during the study
Major surgery other than diagnostic surgery =< 4 weeks prior to registration
Major surgery, including craniotomy, within 14 days before enrollment
Major surgery within 4 weeks
Major surgery within 4 weeks prior to entry to the study (excluding placement of vascular access), or minor surgery within 2 weeks of entry into the study.
Major surgery in the past 8 weeks (Arms 1 and 4)
Major surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.
No major surgery within 4 weeks of first dose of SGI-110.
Major surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.
Major surgery within 14 days before the first dose of study drug and not recovered fully from any complications from surgery.
Any chemotherapy within 4 weeks, or major surgery or radiotherapy within the last 14 days.
Major surgery . 28 days prior to enrollment.
Major surgery, significant trauma, wide-field radiotherapy, or therapy with monoclonal antibodies within 4 weeks before the first dose of study drug
History of major surgery within 4 weeks prior to first dose on this study
